Saturday, August 08, 2026
In Detail Full day, Saturday, August 08, 2026, Timezone: America/Chicago
The AI boom could strengthen Epic's position, health system execs say. Here's where startups and health tech vendors can still win
fiercehealthcare - Clinician-facing AI, imaging AI, patient AI assistants, discharge and care transitions and revenue cycle AI are the categories where health systems are most willing to look beyond Epic, executives said.
AI Summary: Health system executives warn that the surge in AI interest is strengthening incumbent EHR vendors, notably Epic, which can bundle AI features into existing workflows at scale. Startups face an uphill battle unless they target niche integration gaps, interoperability wins or demonstrable ROI — in short, cleverness and agility beat nostalgia for disruption.
- Connecting care: interoperability, prior auth and data exchange (5)
- Epic's AI offensive: UGM rollouts, tools and tokenomics (9)
- Health systems scaling AI: governance, ROI and safety (7)
- Startups and vendors: where to pivot in an Epic world (7)
- All Other Stories
Connecting care: interoperability, prior auth and data exchange
Epic's AI offensive: UGM rollouts, tools and tokenomics
Health systems scaling AI: governance, ROI and safety
Startups and vendors: where to pivot in an Epic world
All Other Stories
AstraZeneca Holds Preliminary Talks with Bristol Myers Squibb on Potential $400 Billion Merger
oncodaily - A deal that could create the world’s fourth-largest drugmaker British pharmaceutical leader AstraZeneca has held confidential, preliminary discussions regarding a potential combination with US rival Bristol Myers Squibb(BMS). A completed […]
AI Summary: AstraZeneca entered preliminary, non-binding talks with Bristol Myers Squibb about a potential $400 billion merger, probing whether combining pipelines and scale could reshape oncology and other businesses. The discussions are early, sparking market speculation and likely regulatory scrutiny as executives weigh strategic synergies against integration complexity and antitrust risk.
Senate Moves to Keep Politics Out of Cancer Research Funding
oncodaily - On August 2, 2026, US senators introduced a bipartisan temporary spending bill aimed at keeping the federal government funded. The bill also included a provision that would pause earlier proposed […]
AI Summary: Lawmakers advanced a bipartisan measure designed to delay a controversial OMB grantmaking rule and protect peer‑reviewed cancer research funding from politicized oversight. Scientific groups welcomed the move as a pragmatic step to preserve grant integrity and ensure researchers can continue work without sudden administrative disruptions.
- Clinical leaders defend peer review, oppose politicized funding (3)
- Inclusion and funding roles shaping cancer clinical research (3)
- Senate stalls OMB rule to shield cancer grants (3)
Clinical leaders defend peer review, oppose politicized funding
Inclusion and funding roles shaping cancer clinical research
Senate stalls OMB rule to shield cancer grants
How a Deadly Superbug Tricks the Immune System to Survive in Hair Follicles
discovermagazine - Learn how Candida auris takes advantage of the skin’s immune response to stay put inside hair follicles.
AI Summary: Researchers show that Candida auris can persist in hair follicles by rewiring local skin immune responses, creating a hidden reservoir that helps the fungus survive disinfection and spread in healthcare settings. The finding explains persistent colonization and suggests new diagnostic and decolonization strategies focused on follicular niches — because apparently this pathogen likes a good hairdo.
Fridge-free tetanus-diphtheria vaccine shows promise of reaching millions worldwide
medicalxpress - The encouraging results of the world's first trial of a fridge-free tetanus-diphtheria vaccine could improve access worldwide to crucial treatments while reducing carbon emissions. Fridge-free vaccines have the potential to transform vaccine delivery by r…
AI Summary: Early studies of fridge‑free vaccine formulations, including a tetanus‑diphtheria candidate, indicate stability without cold storage, promising to reduce discarded doses and simplify distribution in low‑resource settings. If these results hold up, the change could shrink logistical headaches, boost global immunization reach and finally make the vaccine refrigerator’s light a little less terrifying.
Senate Confirms Dr. Erica Schwartz as C.D.C. Director
Apoorva Mandavilli / nytimes - Dr. Schwartz, a deputy surgeon general in the first Trump administration, has publicly supported childhood vaccines.
AI Summary: Senate confirmed Dr. Erica Schwartz as director of the Centers for Disease Control and Prevention after a high-profile nomination process. She will assume leadership of the agency responsible for national disease prevention and public health preparedness, steering CDC policy and operations amid ongoing public‑health challenges and scrutiny of federal responses.
FDA Approved Pluvicto Plus ARPI for PSMA-Positive mAPMN/S Prostate Cancer
oncodaily - On July 31, 2026, the US Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan, marketed as Pluvicto, in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults […]
AI Summary: The FDA has approved an expanded use for a lutetium‑177 radiopharmaceutical (Pluvicto), broadening access for PSMA‑positive metastatic prostate cancer patients and potentially speeding the adoption of targeted radionuclide therapy. Clinicians note the approval could shift treatment sequencing and patient pathways, with implementation details and eligibility criteria guiding real‑world impact.
- Access, dose optimization and real-world data for Lu-177 (4)
- FDA expands Pluvicto approval; industry reaction (3)
- PSMAddition trial: earlier Lu-177 delays metastatic progression (5)
Access, dose optimization and real-world data for Lu-177
FDA expands Pluvicto approval; industry reaction
PSMAddition trial: earlier Lu-177 delays metastatic progression
Mel Mann Highlights First Patient Enrollment in AACR-ADOPT-GEA Trial
oncodaily - Mel Mann, World’s Longest Living Gleevec (Imatinib) / TKI Survivor, 31-year terminal Chronic Myeloid Leukemia (CML) Survivor, Clinical Trial Pioneer, and Patient Advocate, shared American Association for Cancer Research (AACR) […]
AI Summary: The AACR‑affiliated ADOPT‑GEA phase II trial for locally advanced gastroesophageal cancer has reported its first patient enrollment, marking a key milestone in the study's launch. The enrollment signals trial readiness and opens recruitment momentum to evaluate investigational approaches for a challenging cancer subtype, advancing potential new treatment options toward evidence‑based use.
Single dose of psilocybin for depression shows promising results in UK's first publicly funded randomized trial
medicalxpress - The first randomized controlled trial in the U.K. has found that a single dose of psilocybin, the active compound found in "magic mushrooms," produced significant improvements in depression compared with a placebo. This is the first publicly funded random…
AI Summary: A publicly funded randomized trial in the UK found that a single dose of psilocybin, delivered in a clinical setting, produced promising improvements for people with treatment-resistant major depressive disorder. The results suggest psychedelic-assisted therapy could be a viable addition to standard care—pending larger trials and careful safety monitoring—challenging old assumptions about one-and-done fixes.
Some COVID-19 Patients Suffered Heart Damage, an Overlooked Coronavirus Protein May Explain Why
discovermagazine - Discover how the inconspicuous nucleocapsid protein from coronaviruses can trigger hyperinflammation, an effect not typically seen in other viruses.
AI Summary: Scientists identified a previously underappreciated SARS‑CoV‑2 protein that appears to damage heart tissue and may help explain persistent post‑COVID symptoms. The study ties the viral molecule to mechanisms of cardiac injury, opening diagnostic and therapeutic research paths for long COVID cardiac effects — proof that sometimes the troublemaker was hiding in plain sight.
Tufts Medicine CEO, CFO step down amid financial struggles
Jill Hughes / healthcaredive - Chief Executive Mike Dandorph will remain in the position through the end of September, after which he will be replaced by COO Phil Okala. Tufts is also swapping out its chief financial officer.
AI Summary: Tufts Medicine announced the departure of its CEO and CFO amid ongoing financial struggles, prompting a leadership shake‑up as the health system pursues fiscal stabilization. Trustees and executives are now tasked with steadying operations and advancing a turnaround plan while maintaining patient services — the corporate surgery no one asked for.
International project delivers hundreds of next-generation models for cancer research
medicalxpress - Ten years and thousands of patient samples later, the National Cancer Institute (NCI) has published its results from the Human Cancer Model Initiative (HCMI) on the development of 665 organoid models of 25 types of cancer that are now available to scienti…
AI Summary: An international consortium released hundreds of patient‑derived tumor models, including a public HCMI set of 665 organoids, creating a living biobank for drug discovery. Labs worldwide now gain access to diverse, next‑generation models to test therapies and probe cancer vulnerabilities — a major boost for preclinical translational work.
- Experts react: three Nature papers and model summaries (3)
- HCMI release: 665 organoids unveiled in Nature (4)
- Organoids power maps and predictors of therapy resistance (4)
Experts react: three Nature papers and model summaries
HCMI release: 665 organoids unveiled in Nature
Organoids power maps and predictors of therapy resistance
New bipartisan 340B reform bill curbs HHS' rebate pilot
fiercehealthcare - The SUSTAIN 340B Act introduced Wednesday would bring hospital-backed changes, like a clearinghouse to handle improper discounts, and codifies longstanding grey areas in the contentious subsidy program.
AI Summary: Bipartisan lawmakers introduced legislation to rein in HHS’s controversial 340B rebate pilot, pushing back on administrative changes that providers say threaten safety‑net funding. The bill aims to pause or limit the pilot while stakeholders debate drug‑pricing impacts, reimbursements and patient access — the predictable Washington policy scrum.
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Drug Development, Reproductive Health, Obesity, Adolescent Health and look for the RSS link.
StackHealth Time Machine
More StackHealth